KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Net Margin (2016 - 2026)

Neogenomics filings provide 17 years of Net Margin readings, the most recent being 9.16% for Q1 2026.

  • On a quarterly basis, Net Margin rose 626.0% to 9.16% in Q1 2026 year-over-year; TTM through Mar 2026 was 13.3%, a 176.0% decrease, with the full-year FY2025 number at 14.85%, down 293.0% from a year prior.
  • Net Margin hit 9.16% in Q1 2026 for Neogenomics, down from 5.2% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 5.2% in Q4 2025 to a low of 42.17% in Q1 2022.
  • Median Net Margin over the past 5 years was 15.43% (2025), compared with a mean of 17.23%.
  • Biggest five-year swings in Net Margin: plummeted -9056bps in 2022 and later soared 1973bps in 2023.
  • Neogenomics' Net Margin stood at 16.36% in 2022, then soared by 44bps to 9.21% in 2023, then rose by 3bps to 8.91% in 2024, then soared by 42bps to 5.2% in 2025, then crashed by -76bps to 9.16% in 2026.
  • The last three reported values for Net Margin were 9.16% (Q1 2026), 5.2% (Q4 2025), and 14.45% (Q3 2025) per Business Quant data.